Features of the course of liver cirrhosis in the background of infection with COVID-19

Purpose of research. The study of the statistical and clinical features of liver cirrhosis (LC) against the background of a coronavirus infection caused by the SARS-CoV-2 virus. Materials and methods. 98 patients (51 men and 47 women) aged 23 to 69 years (mean age 53.8±1.9 years) with a verified diagnosis of cirrhosis were examined. The patients were divided into 2 groups. Group 1 consisted of 49 patients who underwent surgery in 2020-2021. coronavirus infection. The 2nd group also included 49 patients with cirrhosis who underwent treatment and examination in 2017-2018, which made it possible to exclude infection caused by the SARS-CoV-2 virus in them. Both groups were divided into 2 subgroups: recovered and deceased. A comprehensive statistical processing was carried out. Results. In the subgroups of recovered patients, the results in the dynamics of treatment were positive. The dynamics of liver function indicators in deceased patients of the 1st and 2nd groups also turned out to be similar, but negative. The analysis of cytolysis indicators established their significant progression and more significant in the 1st group. Alkaline phosphatase and gammaglutamyltransferase had the same dynamics, which indicated the progression of cholestasis syndrome. Violations of bilirubin metabolism worsened and also significantly significantly in the 1st group. Worsened protein metabolism. Hemostasis indicators worsened in patients of the 1st group. As expected, the level of C-reactive protein was higher in patients of the 1st group, which was due to a specific inflammatory process of the respiratory organs. Conclusion. Our observations allow us to state that patients with cirrhosis have certain features of the course of the disease against the background of COVID-19 infection, namely, higher rates of liver function decompensation and death when infected with the SORS-CoV-2 virus.

Liver cirrhosis, SARS-CoV-2 virus, COVID-19 infection, examination resalts, disease outcome

1. Some aspects of the treatment of patients with a severe form of coronavirus infection COVID-19. Ed. A. N. Kondratiev. SPb.: Association of Anesthesiologists-Resuscitators of the North-West. 2021. (in Russ.)@@ Некоторые аспекты лечения больных тяжелой формой коронавирусной инфекции COVID-19. Под ред. А. Н. Кондратьева. СПб.: Ассоциация анестезилогов-реаниматолов Северо-Запада. 2021.

2. Temporary guidelines. Prevention, diagnosis and treatment of a new coronovirus infection (Covid-19). Version 15 (02/22/2022). Ministry of Health of the Russian Federation. (in Russ.)@@ Временные методические рекомендации. Профилактика, диагностика и лечение новой короновирусной инфекции (Covid-19). Версия 15 (22.02.2022). Министерство здравоохранения РФ.

3. Krivosheev A.B., Khvan L. A. Post-COVID syndrome: Gastrointerstinal function disorders. Medical Alphbet. 2022; 18: 41-45. (in Russ.) doi: 10.33667/2078-5631-2022-18-41-45.@@ Кривошеев А. Б., Хван Л. А. Постковидный синдром. Расстройство функции желудочно-кишечного тракта. Медицинский алфавит. 2022; 18: 41-45. doi: 10.33667/2078-5631-2022-18-41-45.

4. Bakulin I.G., Bakulina N. V., Tikhonov S. V., Vinchuk S. A., Dekanova V. D., Prokofieva N. A. Pathogenetic links of liver damage, obesity and COVID-19. Medical Alphabet, 2020; 1(30):5-10. (in Russ.) doi: 10.33667/2078-5631-2020-30-5-10.@@ Бакулин И. Г., Бакулина Н. В., Тихонов С. В., Винчук С. А., Деканова В. Д., Прокофьева Н. А. Патогенетические связи повреждения печени, ожирения и COVID-19. Медицинский алфавит, 2020; 1 (30): 5-10. doi: 10.33667/2078-5631-2020-30-5-10.

5. Features of the new coronavirus infection COVID-19 in patients with diseases of the gastrointestinal tract. Temporary guidelines No. 69. Version 1.0 dated 03/30/2020. Moscow. 2020. (in Russ.)@@ Особенности новой коронавирусной инфекции COVID-19 у пациентов с заболеваниями желудочно-кишечного тракта. Временные методические рекомендации № 69. Версия 1.0 от 30.03.2020. М., 2020.

6. Fomina L.A., Melnikova P. S., Gormatyuk D. S. Liver pathology in COVID-19. Medical alphabet. 2022;1(18):25-28. (In Russ.) doi: 10.3366/2078-2022-18-25-28.@@ Фомина Л. А., Мельникова П. С., Горматюк А. С. Поражение печени при COVID-19. Медицинский алфавит. 2022; 18: 25-28. doi: 10.3366/2078-2022-18-25-28.

7. Mekhtiyev S.N., Mekhtieva O. A., Berko O. M. Liver damage in COVID-19: epidemiology, pathogenesis, treatment. effective pharmacotherapy. Gastroenterology. 2022; 18(22):86-92. (in Russ.) doi: 10.33978/23.7-3586-2022-18-22-86-92.@@ Мехтиев С. Н., Мехтиева О. А., Берко О. М. Поражение печени при COVID-19: эпидемиология, патогенез, лечение. Эффективная фармакотерапия. Гастроэнтерология. 2022; 18(22):86-92. doi: 10.33978/23.7-3586-2022-18-22-86-92.

8. Lyalyukova E.A., Dolgalev I. V., Chemysheva E. N., Druk I. V., Konovalova G. M., Lyalyukov A. V. Liver damage while Covid-19: problems of pathogenesis and treatment. Experimental and Clinical Gastroenterology. 2021; 187 (3):178-185. (in Russ.) doi: 10.31146/1682-8658-ecg-187-3-178-185.@@ Лялюкова Е. А., Долгалев И. В., Чернышева Е. Н., Друк И. В., Коновалова Г. М., Лялюков А. В. Поражение печени при COVID-19: патогенез и лечение. Экспериментальная и клиническая гастроэнтерология. 2021; 187(3): 178-185. doi: 10.31146/1682-8658-ecg-187-3-178-185.

9. Yakhontov D. A. Evidence-based medicine in questions and answers. Novosibirsk. LLC «Printing House». 2012 (in Russ.)@@ Яхонтов Д. А. Доказательная медицина в вопросах и ответах. Новосибирск. ООО «Печатный дом». 2012.

10. Drapkina O.M., Maev I. V., Bakulin I. G. Temporary guidelines: Diseases of the digestive system in the context of a pandemic of a new coronavirus infection (COVID-19). Profilakticheskaya Meditsina. 2020;23(3):2120-2152. (In Russ.) doi: 10.17116/profmed202023032120.@@ Драпкина О. М., Маев И. В., Бакулин И. Г. и др. Временные методические рекомендации: Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции (COVID-19). Профилактическая медицина. 2020;23(3):2120-2152. doi: 10.17116/profmed202023032120.